Prescribing information

 

     

BADBIR evaluates the long-term safety and effectiveness of biologic treatments for psoriasis in the UK and ROI.1,2

Explore two analyses from BADBIR, one of the largest national psoriasis registers in the world.1,3

Image showing 2 key results of the study

Latest analysis by the BADBIR group

*Reasons for discontinuation were classified as ineffectiveness and adverse events.

See the independent publication which supports the position of Cosentyx as a first-line biologic in moderate to severe plaque psoriasis.3

This link will take you to the Wiley Online Library website, which is a non-Novartis website.

View the publication

 

Analysis by Novartis using BADBIR data

See the Cosentyx data below demonstrating long-term effectiveness and drug survival.1

Watch now: a 2-minute summary of this data
 

Click here for Cosentyx (secukinumab) prescribing information

About the analysis by Novartis using BADBIR data

 

Icon of a calendar

Observation period1

  • Adults enrolled from 01 January 2016 to 31 August 2018 (still ongoing)
  • Only patients with at least one follow-up visit were included
 

 Icon of people

Patient population1

1679 moderate to severe psoriasis patients treated with the licensed dose of Cosentyx. Of these:

  • ~1/3 biologic-naïve patients (n=507)
  • ~2/3 biologic-exposed patients (n=1172)

 

 

The results

Infographic showing the proportion of biologic-naïve patients in the analysis achieving aPASI less than or equal to 3 over 1 and 2 years.

*Analysis by Novartis using BADBIR data. aPASI ≤3 reflects clear or almost clear skin, or a physician global assessment of 0/1.4

aPASI scores at 12 and 24 months were imputed using data recorded ±90 days of each time point. The fall in patient numbers between Years 1 and 2 reflects fewer patients being on treatment long enough to reach the 2-year time point.1

Line graph showing drug survival rates in the analysis over 2 years

Adapted from Bewley A et al. 2019.1

Adult patients with moderate to severe plaque psoriasis treated with Cosentyx 300 mg enrolled from 01 January 2016 to 31 August 2018 with at least one follow-up visit evaluated were included in this Novartis analysis of the BADBIR registry. The n-numbers reflect those patients meeting each time point. BADBIR approved the statistical analysis plan used.1

aPASI, absolute Psoriasis Area Severity Index; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; PsA, psoriatic arthritis; PsO, plaque psoriasis; ROI, Republic of Ireland.

References

  1. Bewley A et al. Secukinumab 300 mg demonstrates high and sustained effectiveness in treating patients with moderate to severe plaque psoriasis: Real world evidence from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Poster presented at: the 6th Annual Practical Symposium; 8–11 August 2019; Beaver Creek, Colorado, USA.
  2. Burden AD et al. Br J Dermatol 2012;166(3):545–554.
  3. Yiu ZZN et al. Br J Dermatol 2020; doi:10.1111/bjd.18981.
  4. Amatore F et al. J Eur Acad Dermatol Venereol 2019;33:464–483.
COS20-C008e July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]